Cambridge, MA — September 29, 2025 — Leads & Copy — Vyome Holdings, Inc. (Nasdaq: HIND) has acquired substantially all of the assets of Oculo, Inc., an AI startup launched at MIT. The clinical-stage healthcare holding company simultaneously launched a new business unit focused on using AI to tackle inflammation, leveraging Oculo’s assets to develop an AI psychiatrist trained on data from both the US and India. This unit will be overseen by a newly-formed Vyome Board of Directors AI subcommittee comprised of Krishna Gupta, Mohanjit Jolly, and Stash Pomichter, all MIT alumni with AI expertise.
Stash Pomichter, a Director of Vyome, said the company intends to attack inflammation from all angles to limit the usage of steroids and envisions an AI psychiatrist that can diagnose and help treat systemic inflammation by targeting behavioral drivers and biomarkers.
According to Mohanjit Jolly, a Director at Vyome and Partner at Iron Pillar, the market size for digital therapeutics could be greater than $100B over the next decade.
Alay Shah, founder of Oculo, said he’s excited Vyome will carry forth the company’s vision as they target inflammation.
Vyome remains funded through 2026 to progress its core business. The Oculo transaction will have no bearing on the progress of Vyome’s core biotech assets.
Contact:
Stash Pomichter, Director of Vyome
Mohanjit Jolly, Director of Vyome and Partner at Iron Pillar
Alay Shah, founder of Oculo
Source: Vyome Holdings, Inc.
